ARWR

Arrowhead Pharmaceuticals Inc

61.92

Oct 06 • 2:08 PM ET -0.43 (-0.70%)

Healthcare Biotechnology USA Mid NASD

Peers: IONS ALNY BMRN JAZZ ASND CRSP INCY RARE VRTX NBIX

| Held by: VTI IJH VB VBK VXF XBI XMMO MDY IBB IJK

Index	-
Market Cap	8.75B
Enterprise Value	8.52B
Income	-319.95M
Sales	669.50M
Book/sh	3.30
Cash/sh	11.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	711
IPO	Dec 16, 1993

P/E	-
Forward P/E	-
PEG	-
P/S	13.06
P/B	18.77
P/C	5.46
P/FCF	-
EV/EBITDA	-
EV/Sales	12.73
Quick Ratio	5.90
Current Ratio	5.90
Debt/Eq	2.96
LT Debt/Eq	2.86
Option/Short	Yes / Yes

EPS (ttm)	-2.24
EPS next Y	-4.80
EPS next Q	-1.55
EPS this Y	-35408.46%
EPS next Y	-35.19%
EPS next 5Y	-
EPS past 3/5Y	80.60% 57.10%
Sales past 3/5Y	50.52% 56.63%
EPS Y/Y TTM	-80.39%
Sales Y/Y TTM	16.85%
EPS Q/Q	-7.51%
Sales Q/Q	171.02%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	-6.52% 70.36%

Insider Own	5.87%
Insider Trans	-0.48%
Inst Own	83.07%
Inst Trans	-2.99%
ROA	-18.32%
ROE	-64.78%
ROIC	-17.81%
Gross Margin	96.15%
Oper. Margin	-33.82%
Profit Margin	-47.79%
SMA20	-10.89%
SMA50	-22.49%
SMA200	-14.55%
Trades

Shs Outstand	141.13M
Shs Float	132.97M
Short Float	6.97%
Short Ratio	4.85
Short Interest	9.27M
52W High	95.49 -35.16%
52W Low	34.61 78.89%
Volatility	3.11% 5.08%
ATR (14)	3.16
RSI (14)	27.23
Beta	1.34
Rel Volume	0.61
Avg Volume	1.91M
Volume	843,576

Perf Week	-6.54%
Perf Month	-28.29%
Perf Quarter	-27.79%
Perf Half Y	1.20%
Perf YTD	-6.74%
Perf Year	65.11%
Perf 3Y	145.79%
Perf 5Y	6.58%
Perf 10Y	780.73%
Recom	1.12
Target Price	107.83
Prev Close	62.35
Price	61.92
Change %	-0.70%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-26	Resumed	Goldman	Neutral	$74
Sep-08-26	Initiated	Citigroup	Buy	$108
Jul-14-26	Initiated	Stifel	Buy	$98
May-01-26	Initiated	JP Morgan	Overweight	$88
Apr-21-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$100
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75

Show Previous Ratings

Sep-29-26 07:30AM	Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire)
Sep-24-26 08:36PM	RNAi drug specialist ADARx raises $446M IPO (BioPharma Dive)
07:20AM	ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near (Stocktwits)
Sep-23-26 01:45AM	These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. (Barrons.com) -6.82%
Sep-16-26 01:41PM	Not A Gangbusters Launch Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights Massive Pipeline (Stocktwits) -6.91%
03:03PM	Loading…
Sep-15-26 03:03PM	ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data Is This A Sell The News Move? (Stocktwits) -12.40%
01:13PM	FDA clears first generic radioligand drug; Sionna turns to layoffs (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia (Business Wire)
Sep-04-26 12:13PM	This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. (Barrons.com)
Sep-03-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences (Business Wire)
Aug-30-26 11:30AM	Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia (Business Wire)
Aug-24-26 07:30AM	Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress (Business Wire)
Aug-17-26 09:33AM	People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO (plozasiran) as a New Treatment Option to Reduce Triglycerides (Business Wire)
Aug-07-26 06:02AM	Significant demand for Revolution drug; Intellia pinpoints liver toxicity culprit (BioPharma Dive)
Aug-05-26 01:05AM	Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... (GuruFocus.com)
04:17PM	Loading…
Aug-04-26 04:17PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results (Business Wire)
Aug-03-26 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-27-26 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia (Business Wire)
Jul-23-26 11:00AM	Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? (Trefis)
Jul-22-26 06:44PM	ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data (Stocktwits) +19.03%
05:27PM	Arrowhead Shares Soar on Strong Triglyceride Drug Data (The Wall Street Journal)
09:22AM	Why Arrowhead Shot Sky-High, While Its Chief Rival, Ionis, Toppled (Investor's Business Daily)
09:08AM	ARWR Stock On Track To Hit Over 5-Year Highs Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval (Stocktwits)
08:23AM	Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR) (InvestorsHub)
08:01AM	Arrowhead hits best-case scenario with latest results for fat-lowering drug (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia (Business Wire)
Jul-21-26 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results (Business Wire)
Jul-14-26 11:23AM	Arrowhead gains EU authorisation for Redemplo in evolving FCS market (Clinical Trials Arena)
Jul-13-26 02:00AM	Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
07:35AM	Loading…
Jul-10-26 07:35AM	The Long Climb Back For Ionis Stock (Trefis) -9.05%
Jun-24-26 07:54PM	IONS Stock Jumps 4% After-Hours Goldman Sachs Lifts Price Target On Tryngolza Approval (Stocktwits)
Jun-22-26 12:33PM	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
Jun-18-26 07:30AM	Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars (Business Wire)
Jun-02-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events (Business Wire) -5.82%
May-27-26 07:00AM	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 (Business Wire)
May-26-26 10:00AM	Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress (Business Wire)
May-12-26 08:30AM	Wall Street's Cardiac Bet: Where Diagnostics Meet the Money (PR Newswire)
May-07-26 04:49PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press) -6.75%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results (Business Wire)
May-06-26 06:29AM	Arrowhead and Madrigal sign global licence for MASH RNAi therapy (Pharmaceutical Technology) +5.62%
May-05-26 11:53AM	Madrigal outlays $1bn for Arrowheads siRNA MASH asset (Pharmaceutical Technology)
08:00AM	Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals (Business Wire)
May-04-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events (Business Wire)
May-01-26 07:30AM	Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
Apr-24-26 10:45AM	Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings (Pharmaceutical Technology)
06:39AM	Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe (Business Wire)
Apr-21-26 10:04AM	This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. (Barrons.com)
10:03AM	Intel upgraded, Reddit initiated: Wall Street's top analyst calls (The Fly)
Apr-20-26 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results (Business Wire)
Mar-28-26 10:30AM	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo (Business Wire)
Mar-25-26 01:10PM	Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets (Barrons.com) +8.00%
07:03AM	Sarepta sees early success with RNAi drugs from Arrowhead (BioPharma Dive)
Mar-24-26 11:05AM	Anti-Aging Protein Research Takes a Step Forward with Cell Cloning (PR Newswire)
Mar-04-26 08:48PM	Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference (MarketBeat)
Feb-26-26 10:29AM	Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates (Zacks)
Feb-24-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events (Business Wire)
Feb-18-26 12:54AM	Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited (Insider Monkey)
Feb-13-26 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga)
Feb-07-26 10:40AM	Arrowhead price target lowered to $78 from $81 at Morgan Stanley (TipRanks)
Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com)
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -5.02%
04:54PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results (Business Wire)
Feb-04-26 06:15PM	Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 (PR Newswire) -5.66%
Jan-29-26 01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire) +5.40%
Jan-27-26 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia (Business Wire)
Jan-22-26 03:20AM	Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data (Insider Monkey)
Jan-20-26 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results (Business Wire)
Jan-19-26 05:18PM	Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory (Insider Monkey)
Jan-12-26 05:43PM	Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference (MarketBeat)
Jan-11-26 01:09AM	Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) (Insider Monkey)
Jan-07-26 11:05PM	Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants (Business Wire) -7.23%
07:30AM	Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China (Business Wire)
Jan-06-26 06:14PM	Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock (Business Wire) +10.85%
04:29PM	Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss (Investor's Business Daily)
11:26AM	Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. (Barrons.com)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition (Business Wire)
Jan-05-26 07:30AM	Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire) -5.77%
Dec-23-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events (Business Wire)
Dec-15-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.54%
Dec-12-25 08:00AM	Arrowhead price target raised to $80 from $52 at RBC Capital (TipRanks)
Dec-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire) +11.65%
Dec-02-25 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia (Business Wire)
Dec-01-25 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences (Business Wire) +6.74%
Nov-27-25 06:51AM	Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval (Insider Monkey)
Nov-26-25 07:16PM	Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today (Motley Fool) +23.34% -8.68%
05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
12:00AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... (GuruFocus.com)
Nov-25-25 04:00PM	Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results (Business Wire) +5.72%
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +9.42%
Nov-19-25 12:52PM	Arrowhead nets first commercial win as siRNA drug garners FDA approval (Pharmaceutical Technology)
Nov-18-25 11:52AM	Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
07:39AM	RNAi biotech Arrowhead wins first FDA approval (BioPharma Dive)
Nov-06-25 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results (Business Wire)
Nov-04-25 01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences (Business Wire)
Oct-28-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-21-25 07:30AM	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis (Business Wire)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

PhDChristopher Richard Anzalone

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OLUKOTUN ADEOYE Y	Director	Aug 18 '26	Sale	86.96	2,000	173,920	31,600	Aug 20 05:25 PM
PERRY MICHAEL S	Director	Aug 18 '26	Sale	87.30	11,600	1,012,680	111,459	Aug 20 05:22 PM
Adeoye Olukotun	Director	Aug 18 '26	Proposed Sale	86.94	2,000	173,876		Aug 18 05:31 PM
Michael Perry	Director	Aug 18 '26	Proposed Sale	87.26	11,600	1,012,172		Aug 18 05:24 PM
Lu Hongbo	Director	May 12 '26	Sale	76.88	2,970	228,334	52,012	May 14 07:05 PM
Hongbo Lu	Officer	May 12 '26	Proposed Sale	76.87	2,970	228,299		May 12 04:35 PM
Apel Daniel Joseph	Chief Financial Officer	Apr 22 '26	Sale	71.35	13,095	934,285	162,905	Apr 24 06:44 PM
Hamilton James C	Chief Medical Officer	Apr 23 '26	Sale	75.00	10,000	750,000	226,958	Apr 24 06:38 PM
James Hamilton	Officer	Apr 23 '26	Proposed Sale	75.00	10,000	749,998		Apr 23 04:44 PM
Daniel Apel	Officer	Apr 22 '26	Proposed Sale	71.34	13,095	934,206		Apr 22 05:16 PM
Hamilton James C	Chief Medical Officer	Mar 05 '26	Sale	64.19	10,000	641,900	236,958	Mar 09 07:00 PM
James Hamilton	Officer	Mar 05 '26	Proposed Sale	64.19	10,000	641,870		Mar 05 04:49 PM
O'Brien Patrick	COO	Jan 05 '26	Sale	63.11	49,493	3,123,349	474,908	Jan 05 09:50 PM
Hamilton James C	Chief Medical Officer	Jan 05 '26	Sale	63.11	40,164	2,534,661	171,958	Jan 05 09:41 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '26	Sale	66.10	13,187	871,703	3,792,739	Jan 05 09:39 PM
James Hamilton	Officer	Jan 05 '26	Proposed Sale	63.09	39,728	2,506,627		Jan 05 04:59 PM
Patrick O'Brien	Officer	Jan 05 '26	Proposed Sale	63.10	49,493	3,123,172		Jan 05 04:58 PM
Christopher Anzalone	Officer	Jan 02 '26	Proposed Sale	66.10	13,187	871,668		Jan 02 04:04 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Option Exercise	6.15	51,726	318,115	3,857,652	Dec 30 05:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Sale	69.13	51,726	3,575,575	3,805,926	Dec 30 05:46 PM
Ferrari Mauro	Director	Dec 26 '25	Sale	70.00	7,530	527,100	69,053	Dec 30 05:46 PM
Christopher Anzalone	Officer	Dec 29 '25	Proposed Sale	69.13	51,726	3,575,575		Dec 29 04:23 PM
Mauro Ferrari	Director	Dec 26 '25	Proposed Sale	70.00	7,530	527,070		Dec 29 04:03 PM
Waddill William D.	Director	Dec 19 '25	Sale	67.65	8,367	566,038	56,563	Dec 23 06:01 PM
Vakiener Victoria	Director	Dec 19 '25	Sale	67.68	10,040	679,491	35,723	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 19 '25	Sale	67.66	13,445	909,683	3,818,512	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 22 '25	Sale	68.44	12,586	861,340	3,805,926	Dec 23 06:01 PM
OLUKOTUN ADEOYE Y	Director	Dec 19 '25	Sale	67.66	10,000	676,623	33,600	Dec 23 06:01 PM
Christopher Anzalone	Officer	Dec 22 '25	Proposed Sale	68.43	12,586	861,319		Dec 22 04:00 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 17 '25	Sale	64.04	85,000	5,443,462	3,831,957	Dec 19 06:56 PM
Christopher Anzalone	Officer	Dec 19 '25	Proposed Sale	67.66	13,445	909,632		Dec 19 04:08 PM
William Waddill	Director	Dec 19 '25	Proposed Sale	67.65	8,367	566,001		Dec 19 04:07 PM
Adeoye Olukotun	Director	Dec 19 '25	Proposed Sale	67.66	10,000	676,589		Dec 19 04:07 PM
Victoria Vakiener	Director	Dec 19 '25	Proposed Sale	67.68	10,040	679,464		Dec 19 04:06 PM
Christopher Anzalone	Officer	Dec 17 '25	Proposed Sale	64.04	85,000	5,443,253		Dec 17 05:11 PM
Christopher Anzalone	Officer	Dec 16 '25	Proposed Sale	62.58	54,298	3,398,142		Dec 16 04:47 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 15 '25	Sale	68.85	130,000	8,950,615	3,971,255	Dec 16 01:14 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 16 '25	Sale	62.58	54,298	3,398,187	3,916,957	Dec 16 01:14 PM
Christopher Anzalone	Officer	Dec 15 '25	Proposed Sale	68.85	130,000	8,950,580		Dec 15 04:50 PM
PERRY MICHAEL S	Director	Dec 05 '25	Sale	61.03	16,250	991,738	115,240	Dec 09 06:04 PM
Michael Perry	Director	Dec 05 '25	Proposed Sale	60.99	16,250	991,129		Dec 05 04:00 PM
Ferrari Mauro	Director	Nov 28 '25	Sale	56.39	8,750	493,412	68,764	Dec 01 06:10 PM
Mauro Ferrari	Director	Nov 28 '25	Proposed Sale	56.35	8,750	493,062		Nov 28 01:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARWR

Arrowhead Pharmaceuticals Inc

Upgrade your Finviz experience